Track market-moving stories before they get noisy

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Triller To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Triller between October 16, 2024 and December 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 25, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Triller Group Inc. ("Triller" or the "Company") (OTC Pink: ILLR) and reminds investors of the December 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Triller's control over and consolidation of BKFC was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) Defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On October 20, 2025, Triller issued a press release announcing its receipt of a delisting determination letter from the NASDAQ Staff because of its failure to timely file its 2024 10-K, Q1 2025 10-Q, and Q2 2025 10-Q with the SEC. This press release, too, assured investors that Triller was taking necessary steps to prevent the NASDAQ from delisting its securities.

On November 21, 2025, Triller issued a press release announcing its receipt of an additional delisting determination letter from the NASDAQ Staff because of its failure to timely file its quarterly report on Form 10-Q for its third quarter ended September 30, 2025 (the "Q3 2025 10-Q") with the SEC.

On this news, Triller's stock price fell $0.71 per share, or 14.7%, to close at $4.12 per share on November 24, 2025, the next trading day.

Then, on December 30, 2025, Triller issued a press release announcing its receipt of "a determination letter from a Nasdaq Hearings Panel on December 26, 2025, confirming the suspension of trading on the Nasdaq Stock Market effective at the open of the market on December 30, 2025 and delisting of the Company's securities", "stemming from the Company not having been able to file two periodic reports by a deadline of December 24, 2025 set by the Hearings Panel." The press release further disclosed that "[t]he filing delay is attributable primarily to one remaining technical matter involving the consolidation of accounts for a U.S.-based operation within Triller Group"-not yet disclosed to be BKFC.

On this news, Triller's stock price fell $3.38 per share, or 91.35%, over the following two trading sessions, to close at $0.32 per share on December 31, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Triller's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Triller class action, go to www.faruqilaw.com/ILLR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Triller Securities Class Action Lawsuit:

What is the Triller securities fraud lawsuit about?

The lawsuit alleges Triller misled investors about its control over BKFC, financial reporting deficiencies, merger benefits, and its ability to comply with Nasdaq listing requirements, including the risk of delisting.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Triller Group Inc. (OTC Pink: ILLR) securities between October 16, 2024 and December 29, 2025 may be eligible if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by December 14, 2026. Investors may participate without serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Triller securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320649

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Triller To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Triller between October 16, 2024 and December 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Triller Group Inc. ("Triller" or the "Company") (OTC Pink: ILLR) and reminds investors of the December 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Triller's control over and consolidation of BKFC was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) Defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On October 20, 2025, Triller issued a press release announcing its receipt of a delisting determination letter from the NASDAQ Staff because of its failure to timely file its 2024 10-K, Q1 2025 10-Q, and Q2 2025 10-Q with the SEC. This press release, too, assured investors that Triller was taking necessary steps to prevent the NASDAQ from delisting its securities.

On November 21, 2025, Triller issued a press release announcing its receipt of an additional delisting determination letter from the NASDAQ Staff because of its failure to timely file its quarterly report on Form 10-Q for its third quarter ended September 30, 2025 (the "Q3 2025 10-Q") with the SEC.

On this news, Triller's stock price fell $0.71 per share, or 14.7%, to close at $4.12 per share on November 24, 2025, the next trading day.

Then, on December 30, 2025, Triller issued a press release announcing its receipt of "a determination letter from a Nasdaq Hearings Panel on December 26, 2025, confirming the suspension of trading on the Nasdaq Stock Market effective at the open of the market on December 30, 2025 and delisting of the Company's securities", "stemming from the Company not having been able to file two periodic reports by a deadline of December 24, 2025 set by the Hearings Panel." The press release further disclosed that "[t]he filing delay is attributable primarily to one remaining technical matter involving the consolidation of accounts for a U.S.-based operation within Triller Group"-not yet disclosed to be BKFC.

On this news, Triller's stock price fell $3.38 per share, or 91.35%, over the following two trading sessions, to close at $0.32 per share on December 31, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Triller's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Triller class action, go to www.faruqilaw.com/ILLR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Triller Securities Class Action Lawsuit:

What is the Triller securities fraud lawsuit about?

The lawsuit alleges Triller misled investors about its control over BKFC, financial reporting deficiencies, merger benefits, and its ability to comply with Nasdaq listing requirements, including the risk of delisting.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Triller Group Inc. (OTC Pink: ILLR) securities between October 16, 2024 and December 29, 2025 may be eligible if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by December 14, 2026. Investors may participate without serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Triller securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320187

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 22, 2026) - Lead Plaintiff Deadline: December 14, 2026. Investors who purchased (OTC Pink: ILLR) securities between October 16, 2024 and December 29, 2026 may be eligible to recover losses.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Triller securities between October 16, 2024 and December 29, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/triller-group-inc-illr-class_action_lawsuit.

Triller Case Details

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

Triller's control over and consolidation of Bare Knuckle Fighting Championship ("BKFC") was tenuous, overstated, and/or non-existent; Triller was unable to timely file certain periodic financial reports with the SEC, in part due to accounting issues related to its purported control over BKFC; As a result, Triller faced an increased risk of delisting from NASDAQ; Triller's disclosure controls and procedures were deficient, the severity of its financial control issues was understated, and the benefits of the Merger were overstated; Defendants overstated Triller's ability to resolve its non-compliance with NASDAQ's listing requirements; and As a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Triller Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/triller-group-inc-illr-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Triller you have until December 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Triller Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Triller Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319421

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

A Times reporter and editors discuss the challenges of sifting through what's real and what's not in pursuit of the news.

CEO Nir Brenmiller to Join Amsterdam Panel on Decarbonizing Europe's Industrial Base

BrenX Chief Business Officer Doron Brenmiller to Join Industrial Heat Panel at the RTC Summit near Washington, D.C.

Gilad Walker, Chief Business Officer of Brenmiller Europe, to Deliver Keynote in Frankfurt on Integrating Electricity and Heat

New York, New York--(Newsfile Corp. - October 20, 2026) - BrenX Ltd. (NASDAQ: BRNX), a provider of thermal energy storage and integrated industrial energy solutions, today announced that members of its leadership team will speak at three energy industry events this month in Europe and the United States: Reuters Events Energy Transition Europe 2026 in Amsterdam, the Renewable Thermal Collaborative ("RTC") Summit 2026 near Washington, D.C., and the European Commercial and Industrial ("C&I") Energy Storage and Management Summit 2026 in Frankfurt.

Reuters Events Energy Transition Europe 2026, Amsterdam, The Netherlands

Nir Brenmiller, Chief Executive Officer of BrenX, will join the panel "What Will It Take to Decarbonise Europe's Industrial Base?" on Wednesday, October 21, 2026, at 11:50 a.m. CEST. He will be joined by Victor van Hoorn, Director of Cleantech for Europe, and Manus Pandey, Vice President Energy and Climate Policies at Statkraft, with Peter Hulshof, Partner at Systemiq, moderating. The panel will examine which decarbonization pathways can scale for Europe's hardest-to-abate industries, what it will take to move from pilots to full deployment, and the policy, capital and coordination needed to keep industrial investment in Europe.

RTC Summit 2026, Arlington, Virginia, USA

Doron Brenmiller, Chief Business Officer of BrenX, will participate in an industry panel on the future of industrial heat decarbonization on Friday, October 23, 2026, from 11:20 a.m. to 12:00 p.m. ET, at the annual summit of the Renewable Thermal Collaborative, a nonprofit focused on decarbonizing industrial thermal energy use with renewable solutions. The summit takes place from October 21 to 23, 2026 at the Renaissance Arlington Capital View in Arlington, Virginia. The panel will discuss how technologies including thermal energy storage, renewable energy integration and electrification are changing the way industries generate and use heat. Doron Brenmiller will discuss the value of practical, integrated and phased approaches that allow industrial companies to reduce emissions, improve their energy economics and transition from fossil fuels to clean, reliable heat.

European C&I Energy Storage and Management Summit 2026, Frankfurt, Germany

Gilad Walker, Chief Business Officer of Brenmiller Europe S.L. ("Brenmiller Europe"), will deliver a keynote address titled "Electricity Meets Heat: Integrating Renewable Energy, BESS and Thermal Energy Storage for Smarter C&I Energy Platforms" at the summit, which takes place on October 27 and 28, 2026 at the Leonardo Royal Hotel Frankfurt. His keynote will address the integration of renewable energy, battery energy storage systems ("BESS") and thermal energy storage in energy platforms for commercial and industrial sites. Brenmiller Europe is BrenX's joint venture with Integrated Renewable Energy Solutions S.L. ("IRES"). IRES is jointly owned by Green Enesys Group and Viridi RE.

Commercial Progress

The appearances come as BrenX advances the commercial deployment of its bGen™ technology. As announced on October 15, 2026, the Company's 32 MWh bGen™ system at Tempo Beverages ("Tempo") in Israel has reached steam production of approximately 85 tons per operating day during commissioning, above the project's base case of approximately 70 tons per operating day. Commissioning remains ongoing, and sustained operating performance has yet to be confirmed. At Wolfson Medical Center in Israel, civil works are underway on a 12 MWh bGen™ system. In Hungary, BrenX owns an operating 1.2 MWp solar facility at the site of its planned first integrated energy resource center.

"Industrial companies are looking for practical ways to electrify their process heat while keeping their energy costs under control," said Nir Brenmiller, Chief Executive Officer of BrenX. "These events bring together the utilities, industrial operators, developers and policymakers who will shape how that happens. At Tempo, our bGen™ system is producing steam as we work through commissioning, and at Wolfson Medical Center, civil works are underway on our 12 MWh system. We look forward to sharing that progress and to the conversations at each of these events."

Investors and industry participants attending any of these events who would like to meet with BrenX management may contact [email protected].

About BrenX

BrenX provides thermal energy storage and integrated industrial energy solutions. Building on its proprietary bGen™ thermal energy storage technology, the Company is expanding its strategy to develop, own, operate and optimize energy assets that may combine local generation, electrical and thermal storage, grid connectivity, and intelligent energy management around customer needs. BrenX is headquartered in Rosh HaAyin, Israel. For more information, visit www.bren-x.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing: the Company's anticipated participation in the events described in this press release; the timing, progress and results of commissioning and commercial operations at Tempo, including the ability to achieve sustained operating performance; the progress of civil works and the construction, completion and operation of the Wolfson Medical Center project; the planned development of the Company's integrated energy resource center in Hungary; the commercial deployment of bGen™ technology and market opportunities in Europe; and the Company's ability to execute the BrenX strategy. Without limiting the generality of the foregoing, words such as "plan," "potential," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," "seek," "target" or "continue" are intended to identify forward-looking statements.

Readers are cautioned that actual results may differ materially from those expressed or implied by forward-looking statements. Factors that may affect the Company's results include, among others, the Company's ability to complete, commission and operate its projects as planned; construction, integration, performance and customer acceptance risks; the Company's liquidity, capital requirements and ability to obtain additional financing; the effect of financing transactions and anti-dilution provisions on the Company's capital structure; the Company's ability to integrate and realize the anticipated benefits of acquired assets; demand for and market acceptance of the Company's products; competitive, technological, supply-chain, regulatory and commercial risks; and political, economic and military instability in Israel and the Middle East. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those described under "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 25, 2026, and in the Company's subsequent SEC filings. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320010

Source: BrenX Ltd.

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Triller Group Inc. (OTC Pink: ILLR) between October 16, 2024 and December 29, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026.

SO WHAT: If you purchased Triller securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Triller's control over and consolidation of Bare Knuckle Fighting Championship ("BKFC") was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319883

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Triller Group Inc. (OTC Pink: ILLR) between October 16, 2024 and December 29, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026.

SO WHAT: If you purchased Triller securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Triller's control over and consolidation of Bare Knuckle Fighting Championship ("BKFC") was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319593

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Triller Group Inc. (OTC Pink: ILLR) between October 16, 2024 and December 29, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026.

SO WHAT: If you purchased Triller securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Triller's control over and consolidation of Bare Knuckle Fighting Championship ("BKFC") was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319580

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SHAKOPEE, Minn.--(BUSINESS WIRE)-- #BackupPower--Two UPS systems by CyberPower were given top ratings from NY Times' Wirecutter reviews for home use during a power outage.

This is going to bring a lot of problems that almost anyone could have predicted

The New York Times Company (NYSE:NYT – Get Free Report) announced a quarterly dividend on Friday, September 25th. Investors of record on Wednesday, October 7th will be paid a dividend of $0.23 per share on Thursday, October 22nd. This represents a $0.92 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Wednesday, October 7th.

New York Times has raised its dividend by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 7 consecutive years. New York Times has a payout ratio of 39.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect New York Times to earn $3.11 per share next year, which means the company should continue to be able to cover its $0.92 annual dividend with an expected future payout ratio of 29.6%.

Shares of NYT stock opened at $62.78 on Monday. New York Times has a 12-month low of $54.10 and a 12-month high of $87.10. The firm has a fifty day moving average of $67.58 and a 200-day moving average of $73.76. The firm has a market capitalization of $10.13 billion, a price-to-earnings ratio of 26.16, a price-to-earnings-growth ratio of 1.62 and a beta of 0.93.

New York Times (NYSE:NYT – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. New York Times had a net margin of 13.19% and a return on equity of 22.64%. The business had revenue of $762.46 million for the quarter, compared to analyst estimates of $752.01 million. During the same period last year, the business posted $0.58 earnings per share. The firm’s quarterly revenue was up 11.2% on a year-over-year basis. Research analysts expect that New York Times will post 2.84 earnings per share for the current year. Institutional Investors Weigh In On New York Times Institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC purchased a new stake in New York Times in the second quarter worth approximately $2,565,000. Resona Asset Management Co. Ltd. purchased a new position in New York Times during the 1st quarter valued at $1,752,000. Berkshire Hathaway Inc bought a new position in shares of New York Times in the 4th quarter worth approximately $351,664,000. Engineers Gate Manager LP lifted its stake in shares of New York Times by 832.5% during the 2nd quarter. Engineers Gate Manager LP now owns 50,791 shares of the company’s stock valued at $3,554,000 after buying an additional 45,344 shares in the last quarter. Finally, LGT Fund Management Co Ltd. lifted its stake in shares of New York Times by 27.8% during the 1st quarter. LGT Fund Management Co Ltd. now owns 70,463 shares of the company’s stock worth $5,900,000 after acquiring an additional 15,321 shares during the last quarter. Hedge funds and other institutional investors own 95.37% of the company’s stock.

About New York Times (Get Free Report)

The New York Times Company is a media and information company best known for publishing The New York Times, a global news organization founded in 1851. The company produces journalism across national and international news, politics, business, culture, science, sports and opinion, distributing its content through digital platforms and the newspaper’s print edition.

In addition to its core news business, the company offers a range of subscription products and services, including NYT Cooking, Games, Audio and Wirecutter, a product-recommendation service.

Further Reading Five stocks we like better than New York Times Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam? The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for New York Times Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New York Times and related companies with MarketBeat.com's FREE daily email newsletter.

New York Times (NYSE:NYT – Get Free Report) and MediaCo (NASDAQ:MDIA – Get Free Report) are both communication services companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Insider & Institutional Ownership 95.4% of New York Times shares are held by institutional investors. Comparatively, 64.0% of MediaCo shares are held by institutional investors. 1.9% of New York Times shares are held by company insiders. Comparatively, 9.8% of MediaCo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings This table compares New York Times and MediaCo”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio New York Times $2.82 billion 3.64 $343.98 million $2.40 26.59 MediaCo $139.42 million 0.66 -$69.74 million ($0.83) -1.31 New York Times has higher revenue and earnings than MediaCo. MediaCo is trading at a lower price-to-earnings ratio than New York Times, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings This is a breakdown of recent ratings and price targets for New York Times and MediaCo, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score New York Times 0 5 5 1 2.64 MediaCo 1 0 0 0 1.00 New York Times presently has a consensus price target of $84.20, indicating a potential upside of 31.96%. Given New York Times’ stronger consensus rating and higher probable upside, equities analysts plainly believe New York Times is more favorable than MediaCo.

Profitability This table compares New York Times and MediaCo’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets New York Times 13.19% 22.64% 15.58% MediaCo N/A N/A N/A Volatility and Risk New York Times has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, MediaCo has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.

Summary New York Times beats MediaCo on 14 of the 15 factors compared between the two stocks.

About New York Times (Get Free Report)

The New York Times Company, together with its subsidiaries, creates, collects, and distributes news and information worldwide. The company operates through two segments, The New York Times Group and The Athletic. It offers The New York Times (The Times) through company’s mobile application, website, printed newspaper, and associated content, such as podcast. The company also offers The Athletic, a sports media product; Cooking, a recipe product; Games, a puzzle games product; and Audio, an audio product. In addition, it offers a portfolio of advertising products and services to advertisers, such as luxury goods, technology, and financial companies, to promote products, services or brands on digital platforms in the form of display ads, audio and video, in print in the form of column-inch ads, and at live events; and Wirecutter, a product review and recommendation product. Further, the company licenses content to digital aggregators in the business, professional, academic and library markets, and third-party digital platforms; articles, graphics, and photographs, including newspapers, magazines, and websites; and for use in television, films, and books, as well as provide rights to reprint articles, and create and sell new digests. Additionally, it engages in commercial printing and distribution for third parties; and operates the NYTimes.com website. The company was founded in 1851 and is headquartered in New York, New York.

About MediaCo (Get Free Report)

MediaCo Holding Inc. owns and operates radio stations in the United States. The company engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City area. It also offers digital advertising, and events, which includes sponsorships, ticket sales, licensing, and syndication services. MediaCo Holding Inc. was incorporated in 2019 and is headquartered in New York, New York.

Receive News & Ratings for New York Times Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New York Times and related companies with MarketBeat.com's FREE daily email newsletter.

Shares of The New York Times Company (NYT +1.87%) plunged this week, falling as much as 11.9%, before recovering on Thursday to a 9.8% decline as of 2:09 p.m. EDT, according to data from S&P Global Market Intelligence.

On Wednesday, major shareholders, including the State Board of Administration of Florida (SBA) and the National Center for Public Policy Research (NCPPR), filed a lawsuit against The New York Times, alleging bias in its coverage of the Israel-Hamas war and associated damage to the paper's reputation.

Whether the suit will be successful and what financial impact it will have on the company's financials remain unknown; however, it appears that at least some shareholders perceived sufficient risk to sell shares upon the suit's announcement.

Premium Feature

Moneyball Superscore

83/100

Today's Change

(

1.87

%) $

1.16

Current Price

$

63.05

Did the New York Times damage its credibility? The plaintiffs claim that, since the Times mentions its credibility and brand reputation as a core business asset in its financial documents, and that a perception of unreliable reporting could hurt the company's brand, shareholders are entitled to know whether management and/or the Board of Directors have cultivated a culture of bias, either intentionally or through negligence.

The suit asks a judge to compel the Times to hand over internal documents related to the Israel-Hamas war that the plaintiffs have already sought and that the Times has refused to provide for four months. Four months ago, in May, a protest was held outside the Times' New York City office following a particularly inflammatory op-ed that the Times published that week and refused to retract.

The plaintiff's suit is grounded in the testimony of an internal whistleblower, who spent a decade on the Times' video desk. The whistleblower claims she raised concerns about bias in the paper's coverage of Israel at least 15 times between 2019 and 2026, exhausting all official channels to no avail. The unnamed whistleblower made a statement to The Free Press this week saying, "The public deserves a better picture of how the Times manufactures the news when Jews or Israel are involved."

The plaintiffs also disclosed numerous examples given by the whistleblower to The Free Press, which appear quite disturbing if proven true by internal documents. One particular example was The Times hiring a freelance video journalist in Gaza to cover the war shortly after the attack of Oct. 7, 2023, who the Times had already stopped using in 2022 after the journalist's social media posts had praised Adolf Hitler.

Image source: Getty Images.

The New York Times denies the allegations Unsurprisingly, The Times rejected the lawsuit's claims, with a spokesperson stating to The Free Press:

This lawsuit has no merit and was brought for an improper purpose. Although it is positioned as a corporate governance petition to inspect the company's books and records, it is a transparent attempt to exert agenda-driven pressure against an independent media organization, level false allegations of bias, and chill journalism protected by the First Amendment.

Currently, whether the Times' coverage of the Israel-Hamas war is biased or not doesn't appear to be harming financial results, at least not yet. The Times has posted low-double-digit revenue growth in each of the last three quarters and has beaten revenue and earnings expectations every quarter over the past year. However, the last reported quarter ended in June, shortly after the May protest.

Additionally, The New York Times is involved in other lawsuits, but as the plaintiff. The Times is currently suing several AI model companies over the unlicensed use of its copyrighted work. This copyright issue is one that all media companies are looking to profit from in the AI era.

The outcome of these lawsuits on all sides remains uncertain, but one thing is for sure: The Times will likely incur additional legal costs in the near- to medium-term, both as plaintiff and defendant. Perhaps shareholders anticipate these cost headwinds, with shares down 8.2% year to date.

OpenAI committed "an astonishing theft of unprecedented proportions" when it used millions of news articles to train its artificial intelligence models, The New York Times alleged in a court document unsealed Thursday.

Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in coming weeksNew York, New York and Rockville, Maryland--(Newsfile Corp. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has achieved full alignment with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) on its pending Conditional Marketing Authorisation Application (CMAA). MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors presented in its most recent Scientific Advice Meeting (SAM) - was appropriate in the orphan indication Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma. Further, the Company achieved full alignment on the proposed design of its upcoming confirmatory Phase 3 trial design – including the proportion of patients to be dosed with remaining Phase 2 drug product versus forthcoming Phase 3 material. The Phase 3 trial is required to have commenced prior to being granted a CMAA. OS Therapies expects to complete the CMAA submission in the coming weeks. The Company also intends to commence the confirmatory Phase 3 as soon as possible in the fourth quarter of 2026 and site outreach has commenced accordingly.

The MHRA's supportive advice aligns with the Agency's recently published Rare Disease Regulatory Framework (https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework/draft-rare-disease-therapies-regulatory-framework); and advice from the European Medicines Agency (EMA) pertaining to a forthcoming CMAA via the pan-European Centralised Procedure.

"Achieving full alignment with MHRA and EMA, which paves the way for our upcoming CMAA submissions, and the initiation of our confirmatory Phase 3 trial is a major achievement," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "With this full alignment now in hand, and with it the recognition from international regulators that the standard of care in Osteosarcoma has not meaningfully changed in the last forty years, we are bringing this to the U.S. Food & Drug Administration (FDA). The FDA is part of the Orbis Project that coordinates approvals between international regulators, including the UK. The FDA is considering the ongoing Biologics License Application (BLA) submission that began in January 2026, with potential early market access under the Accelerated Approval Program. Additionally, the EMA recently informed the Company that a previously requested SAWP meeting was no longer required prior to submission of the CMAA to EMA."

OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the FDA, and ODD, FTD and Advanced Therapy Medicinal Products (ATMP – RMAT equivalent in the EU and UK) from the EMA and MHRA. Under the RPDD program, if the Company is granted a BLA in the United States, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. The most recent PRV sale occurred in August 2026 for $220 million. However, there can be no assurance that the Company would realize a comparable value, if any, in connection with any future PRV sale. OS Therapies has completed resubmission of a Regenerative Medicine Advanced Therapy (RMAT) request and the Company's Commissioner's National Priority Review Voucher (CNPV) letter of intent has been accepted by FDA. The Company intends to request Rolling Review of the ongoing BLA submission that began in January 2026 following its upcoming mid-September 2026 FDA Type C Statistical Methods Meeting. OS Therapies is seeking to obtain a BLA under the Accelerated Approval Program in the U.S. and Conditional Marketing Authorization Applications (CMAAs) in Europe, the U.K. and Australia for OST-HER2 in metastatic osteosarcoma in the fourth quarter of 2026.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.

The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma, demonstrating clinically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study and the overall survival (OS) secondary endpoint. The Company is seeking a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving Conditional Marketing Authorisation Applications from the U.K.'s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 was previously conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. The Company has also completed dosing in a Phase 1 study of OST-504 for castration-resistant prostate cancer.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicon Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release regarding future expectations, plans, prospects or performance, as well as any other statements that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are generally identified by words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "should," "will" and similar expressions, although not all forward-looking statements contain these words. These statements are based on the current expectations and assumptions of OS Therapies and its management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the Company's expectations regarding its cash runway; the timing, amount and receipt of VAT refunds and R&D tax credits; the Company's ability to obtain additional financing on acceptable terms or at all; the timing and outcome of regulatory submissions and potential approval of OST-HER2 by the U.S. Food and Drug Administration and applicable foreign regulatory authorities; and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date of this press release, and OS Therapies undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/314396

Source: OS Therapies

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The New York Times Company (NYT) Citi's 2026 Global TMT Conference September 9, 2026 9:30 AM EDT

Company Participants

William Bardeen - Executive VP & Chief Financial Officer

Conference Call Participants

Jason Bazinet - Citigroup Inc., Research Division

Presentation

Jason Bazinet
Citigroup Inc., Research Division

Welcome, everyone. We're super excited to have Will Bardeen, CFO of The New York Times, with us this morning. Will, thank you so much for coming.

William Bardeen
Executive VP & Chief Financial Officer

Thanks, Jason. Great to be here.

Question-and-Answer Session

Jason Bazinet
Citigroup Inc., Research Division

So I want to kick off, I really like your origin story, maybe I have this wrong, but I think you -- before you became the CFO, you were, sort of, integral in designing, sort of, the firm's digital strategy. Is that fair?

William Bardeen
Executive VP & Chief Financial Officer

Yes. I think that is fair. I've been in the CFO seat for 3 years, but had begun as the head of strategy all the way back in 2010.

Jason Bazinet
Citigroup Inc., Research Division

In 2010. And I think your story is interesting just because not -- I can't think of many companies that have been as successful in this digital pivot as you have been. So I give a lot of credit for being the, sort of, architect of this. But my question is, as you've watched this strategy unspool over -- what are we now, do you say, 2010?

William Bardeen
Executive VP & Chief Financial Officer

Yes. So I mean part of the leadership team over the last, say, 15 years, that has -- I mean, I think, at this stage, fair to say, The Times has transformed into a digitally native company that's innovating rapidly.

Jason Bazinet
Citigroup Inc., Research Division

U.S. President Donald Trump's administration sided with OpenAI in a lawsuit brought by The New York Times, defending training AI models on copyrighted works, according to a court document filed Tuesday.

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - September 2, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Wix.com Ltd. ("Wix" or the "Company") (NASDAQ: WIX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=j1sJVrcgKOI

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-wix/

Wix investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3653 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wix/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, Wix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the competitiveness and performance of its AI product offerings relative to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852.

WHAT TO DO? If you invested in Wix and suffered a loss during the relevant time frame, you have until September 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3653
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312743

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The Trump administration has filed a brief supporting OpenAI in its dispute with the New York Times (NYT.N) and other newspapers ​over the company's use of their work to train the large language models behind ‌ChatGPT, saying AI training generally makes fair use of copyrighted material.

The brief, filed in Manhattan federal court on Tuesday, appears to be the first time the U.S. government has weighed in on a wave of cases brought by copyright owners including ​authors, publishers, music labels and news outlets over AI training. A brief has advisory rather than ​legal weight but could bolster tech companies as they fight the claims.

"The United States has ⁠a strong interest in this court rejecting any argument that training LLMs on copyrighted texts violates ​copyright law" based on concerns including scientific advancement and national security, the brief said.

Spokespeople for the Times and ​OpenAI did not immediately respond to requests for comment on the filing on Wednesday.

"AI dominance is critical to promote national security, prosperity, and economic mobility for all Americans," U.S. Associate Attorney General Stanley Woodward said in a statement posted ​to X. "This Administration will never let our Nation be at a disadvantage relative to our foreign adversaries ​based on a plainly incorrect understanding of copyright law."

U.S. Commerce Secretary Howard Lutnick separately told G20 officials at a meeting in ‌North ⁠Carolina on Wednesday that their countries should embrace fair use and allow AI companies to train their models on creators' work while finding a way to "protect artists."

The Times' lawsuit, first filed in 2023, accuses OpenAI and its largest financial backer, Microsoft (MSFT.O), of using millions of newspaper articles without permission to train OpenAI's popular ​chatbot. The case is one ​of dozens brought by ⁠copyright holders against tech companies such as OpenAI, Anthropic and Meta Platforms for what they say is misuse of their material to train AI systems.

All of ​the pending cases will likely revolve around whether AI systems make fair ​use of copyrighted ⁠material by using it to create new, transformative content. The first two judges to consider the issue issued diverging rulings last year.

The government agreed on Tuesday with tech companies that AI training is "extraordinarily" transformative.

"Beyond the subject matter ⁠of ​this litigation, LLMs are already helping researchers across fields achieve major ​breakthroughs," the brief said. "Constraining LLM development under a misunderstanding of fair use doctrine would thwart such creative and scientific progress while ​hindering American prosperity and economic mobility."

 | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York.

Citi’s 2026 Biopharma Back to School Conference
Format: Fireside chat and one-on-one investor meetings
Date and Time: Wednesday, September 9, 2026, 4:20 p.m. to 4:55 p.m. ET
Location: JW Marriott Essex House, 160 Central Park South, New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company presentation and one-on-one investor meetings
Date and Time: Monday, September 14, 2026, 9:00 a.m. to 9:30 a.m. ET
Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY

Deutsche Bank 2026 Healthcare Summit
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 16 - Thursday, September 17, 2026
Location: Deutsche Bank Center, One Columbus Circle, New York, NY

Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 23 - Thursday, September 24, 2026
Location: New York, NY

Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their conference representative.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Sumedh Sunkaraneni
Ascentage Pharma
[email protected]
+1 (301) 792-6286

Brian Korb
astr partners
[email protected]
+1 (917) 653-5122

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Wix.com Ltd. ("Wix" or the "Company") (NASDAQ: WIX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=j1sJVrcgKOI

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-wix/

Wix investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3653 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wix/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, Wix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the competitiveness and performance of its AI product offerings relative to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852.

WHAT TO DO? If you invested in Wix and suffered a loss during the relevant time frame, you have until September 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312228

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Wix.com Ltd. ("Wix" or the "Company") (NASDAQ: WIX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=j1sJVrcgKOI

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-wix/

Wix investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3653 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wix/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, Wix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the competitiveness and performance of its AI product offerings relative to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852.

WHAT TO DO? If you invested in Wix and suffered a loss during the relevant time frame, you have until September 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3653
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311759

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

President Donald Trump on Sunday lashed out at NBC News "Meet the Press" host Kristen Welker, suggesting she would be reported to the Federal Communications Commission over her alleged characterization of election results.

The president slammed Welker after Trump said the "Meet the Press" host said that he has had "mixed results" with candidates he has endorsed during this election cycle. A handful of Trump's chosen candidates have lost in primaries this year, such as Minnesota gubernatorial candidate and MyPillow CEO Mike Lindell and Iowa gubernatorial candidate Rep. Randy Feenstra, R-Iowa.

"How can anyone be allowed to say this, working for freely given Public Airwaves?" Trump said in a Truth Social post. "Because of this purposeful inaccuracy, she will be reported to the FCC for rebuke or punishment."

Welker's comments were not made on Sunday's broadcast of "Meet the Press." Instead, the NBC host made the remark during a pre-show segment on a local Washington, D.C., affiliate, WRC-TV, CNN's Brian Stelter said in a post on X.

"He's going to loom large over these midterms. There's no doubt about that. He, of course, has endorsed a slate of candidates in the primaries," Welker said in that segment. "He's had some mixed results, but most recently, his pick of Senator Darline Graham, of course, the sister of the late Senator Lindsey Graham, was successful in her primary battle, so now she takes on Dr. Annie Andrews in South Carolina."

A spokesperson for NBC News said in a statement: "Kristen is one of the best in the business and we stand by her." 

The president's attack on Welker comes after the Treasury Department barred economics journalists from The New York Times, The Wall Street Journal and Bloomberg from attending this week's G20 meetings in North Carolina, according to the Times.

The reporters were not granted credentials by the Treasury Department.

Nearly 300 members of the media, including one Times reporter, will have high-level access to policymakers throughout the event, a Treasury spokesperson said in a statement.

The exclusions are the latest example of the Trump administration seeking to restrict press access. Last year, the Pentagon imposed a strict new press policy that saw nearly all media outlets exit rather than sign an agreement to abide by the policy.

While Trump has long derided the news media as "fake news" and lashed out at reporters, his Federal Communications Commission chief Brendan Carr has been more willing to act on alleged bias during his second term. Last year, Carr called for action against Jimmy Kimmel over comments made on his ABC late-night show. ABC later temporarily pulled the program from the air before restoring it.

Trump appeared to direct Carr to target NBC in his social media post.

"The Press is a Disgrace to our Nation, and I hope that Chairman Brendan Carr, and the fine people of his Commission, will take this Threat to our Country very seriously," he said.

In an earlier Truth Social post, Trump expressed his displeasure with polling used by the press to forecast election results, and suggested Carr's FCC would also look into that.

"THE FAKE POLLS USED BY OUR CROOKED MEDIA ARE OUT OF CONTROL, AND SOMETHING MUST BE DONE ABOUT IT. FCC TO THE RESCUE!" the president said.

The president stormed out of an interview with Welker earlier this year after being pressed on his controversial "weaponization" fund and on evidence of his persistent claims of election fraud.

Abacus FCF Advisors LLC purchased a new position in shares of The New York Times Company (NYSE: NYT) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 76,966 shares of the company's stock, valued at approximately $5,386,000. Several other hedge funds also

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Wix.com Ltd. ("Wix" or the "Company") (NASDAQ: WIX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=j1sJVrcgKOI

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-wix/

Wix investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3653 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wix/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, Wix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the competitiveness and performance of its AI product offerings relative to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852.

WHAT TO DO? If you invested in Wix and suffered a loss during the relevant time frame, you have until September 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309938

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us